Drug utilization and medication costs at the end of life

Lisa Pont*, Kristian Jansen, Margrete Aase Schaufel, Dagny Faksvåg Haugen, Sabine Ruths

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


In the end stages of life, drug treatment goals shift to symptom control and quality of life and as such changes in drug utilization are expected. The aim of this paper is to review the extent to which costs are considered in drug utilization research at the end of life, with a particular focus on the outcome measures being used. This systematic review identified seven studies across varied settings studies reporting both drug utilization and medication cost outcome measures. The main factors identified that impacted medication use and cost were the time period considered and the provision of specialist palliative care services. Combining drug utilization and medication cost outcomes is critical for the allocation of healthcare resources and the development of a sound health policy.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number2
Publication statusPublished - 3 Mar 2016


  • drug utilization
  • End-of-life
  • medication costs
  • palliative care
  • systematic review


Dive into the research topics of 'Drug utilization and medication costs at the end of life'. Together they form a unique fingerprint.

Cite this